News Results for Novacyt S.A (NCYT)

  • 03 Jun
    Novacyt to settle debt repayments early following cash generation

    Anglo-French diagnostics company Novacyt said it would settle €7m of principal debt with Harbert European Growth Capital and Vatel Capital by the end of June. The early settlement of the HEGC loan...

  • 02 Jun
    Novacyt Covid-19 test sales, orders reach €135m

    Anglo-French group Novacyt said sales and confirmed orders for its Covid-19 test had reached €135m (£120m). The figure included sales of €45m and orders of €90m. Novacyt said it was now selling...

  • 18 May
    Director Deals - Novacyt S.A (NCYT)

    James Wakefield, Chairman, bought 20,000 shares in the company on the 15th May 2020 at a price of 304.90p. The Director now holds 36,839 shares. Story provided by Director...

  • 18 May
    Director Deals - Novacyt S.A (NCYT)

    Graham Mullis, Chief Executive Officer, bought 9,493 shares in the company on the 15th May 2020 at a price of 310.00p. The Director now holds 61,631 shares. Story provided by

  • 23 Mar
    Novacyt gets FDA emergency authorisation for Covid-19 test

    Dual-listed Paris based company Novacyt said the US Food and Drug Administration had issued an emergency use authorization for its Covid-19 test. Hospitals and laboratories in the US would now be...

  • 16 Mar
    Novacyt gets orders from Public Health England for coronavirus test

    Dual-listed Paris based company Novacyt said Public Health England had started ordering its coronavirus test. Orders were initially for eight hospitals, to provide stocks in those locations for...

  • 28 Feb
    Novacyt inks distribution agreement for coronavirus test

    Dual-listed Paris-based company Novacyt said it had signed its first major distribution agreement for its coronavirus test, with a global life sciences company. The company would supply the test...

  • 17 Feb
    Novacyt launches CE-marked coronavirus test

    Dual-listed Paris based company Novacyt said it had launched a CE-mark approved coronavirus test. The company had already reported strong demand for its research-use-only test, launched on 31...

  • 07 Feb
    Novacyt enjoys strong demand for coronavirus test

    Dual-listed Paris based company Novacyt said it had experienced strong demand for its coronavirus test following the major outbreak of the disease originating in China. The company launched the...

  • 31 Jan
    UK stocks tumble on virus fears and Eurozone weakness

    UK stocks tumbled on Friday due to weak Eurozone growth and rising fears over the coronavirus. US stock markets also felt the strain with the S&P 500 opening 0.45% lower to 3,268 and the Dow...

  • 22 Mar
    Novacyt signs development contract with GenePOC

    Novacyt's molecular testing division, Primerdesign, has entered into a clinical assay development contract with GenePOC, a Canada-based company which specialises in the development and manufacture...

  • 24 Jan
    Novacyt boosts FY revenue by 35%

    Clinical diagnostics group Novacyt said it boosted sales by 35% in 2017, with all parts of the company achieving double-digit sales growth. The company ended the year with €4.3m (£3.8m) in cash....

  • 02 Jan
    Novacyt makes fast-growing companies list

    Novacyt said it has been ranked 135 in Deloitte's Technology Fast 500 EMEA index. The awards rank 500 technology, media and telecommunications companies with the highest rate of growth in Europe,...

  • 07 Nov
    Novacyt wins French award

    Novacyt said it has won the Ile-de-France award of the Deloitte Technology Fast 50 French programme, an initiative that recognizes fast-growing companies. It is the second consecutive year that it...

Shares Magazine

Shares Magazine

Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.

Don't miss the latest news! Sign up today

Investor Events

Investor Events

Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.

Terms & Conditions | Privacy Policy | Cookies